SCHEMBL26669331

SCHEMBL26669331

C=Cc1cc(S(N)(=O)=O)c(C)nc1Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.42
▸ CA2 P00918 4/20 0.42
▸ LMNA P02545 1/20 0.41
▸ AR P10275 1/20 0.41
▸ KIF11 P52732 2/20 0.39
▸ EGFR P00533 1/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ DHODH Q02127 4/20 0.39
▸ EPHX2 P34913 1/20 0.38
▸ PTGES2 Q9H7Z7 1/20 0.38
▸ TRPV1 Q8NER1 2/20 0.38
▸ CA9 Q16790 4/20 0.37
▸ CA12 O43570 3/20 0.37
▸ FLT3 P36888 1/20 0.36
▸ PRKCD Q05655 1/20 0.36
▸ CAMK2B Q13554 1/20 0.36
▸ CAMK2G Q13555 1/20 0.36
▸ CAMK2D Q13557 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26669276 0.85 GAA (0.40) LMNAARKIF11TRPV1MAPT
SCHEMBL29704119 0.74 CA2 (0.45) CA1CA2KIF11DHODHPTGES2
SCHEMBL24497321 0.70 TNNI3K (0.50) EGFRDHODHFLT3MAPTCDK1
SCHEMBL26669266 0.69 PTGS2 (0.43) CA1CA2EGFREPHX2CA9
SCHEMBL14768056 0.65 AURKA (0.54) EGFRKDRFLT3CAMK2GCAMK2D
SCHEMBL26488750 0.64 DHODH (0.54) EGFRPDGFRBKDRDHODHEPHX2
SCHEMBL29704141 0.64 LMNA (0.49) CA1CA2LMNAARKIF11
SCHEMBL31332041 0.64 LMNA (0.53) CA2LMNAAREGFRCA9
SCHEMBL20766320 0.64 PTGES2 (0.65) CA1CA2LMNAARKIF11
SCHEMBL20766416 0.64 CA2 (0.71) CA1CA2KIF11CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4281073-A1 COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER Ikena Oncology, Inc. (US) 2023-11-29 — — EP disclosed
WO-2022159986-A1 COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER Ikena Oncology, Inc. (US) 2022-07-28 — — WO disclosed
Send feedback